Business Context and Reporting Period
Company: IOVANCE BIOTHERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: March 17, 2026
Reporting Period: Specific event date of March 17, 2026.
Context: The filing discloses the departure of a member of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
Board Departure: On March 17, 2026, Wendy Yarno, a member of the Board of Directors, notified the Board of her intention to retire. She will not stand for re-election at the Company's annual meeting of stockholders, currently anticipated to be held in June 2026. Ms. Yarno will serve out her current term until that meeting.
Guidance, Outlook, and Management Commentary
- Reason for Departure: The Company explicitly states that the decision to retire is not due to any disagreement between the Company and Ms. Yarno regarding operations, policies, or practices.
- Management Commentary: The Company expressed gratitude for Ms. Yarno's service to the Board.
- Risks and Contingencies: No specific risks, contingencies, or unusual items were disclosed in this filing.
- Guidance: No financial guidance or operational outlook was provided.
Important Facts for Investor Verification
- Confirm the exact date of the upcoming Annual Meeting of Stockholders (anticipated for June 2026) to verify the end of Ms. Yarno's term.
- Verify if the Board has initiated a search for a replacement director to fill the vacancy upon Ms. Yarno's retirement.
- Review subsequent filings to ensure no undisclosed disagreements or material events related to the Board composition have emerged.